Literature DB >> 25493952

Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease.

Elaine Ku1, David V Glidden2, Kirsten L Johansen3, Mark Sarnak4, Hocine Tighiouart5, Barbara Grimes2, Chi-Yuan Hsu3.   

Abstract

There is controversy regarding whether strict blood pressure control is indicated in chronic kidney disease (CKD) since the primary results of randomized controlled trials failed to show any impact on progression of kidney disease with this strategy. However, strict blood pressure control may have other beneficial effects beyond reducing the risk of end-stage renal disease (ESRD), such as lowering mortality after ESRD onset. The Modification of Diet in Renal Disease (MDRD) trial randomized 840 patients with CKD to strict (mean arterial pressure under 92 mm Hg) versus usual (mean arterial pressure under 107 mm Hg) blood pressure control between 1989 and 1993. Here we extended follow-up of study enrollees by linkage with United States Renal Data System and National Death Index to ascertain ESRD and vital status through 2010. Overall, 627 patients developed ESRD through 2010 with a median follow-up of 19.3 years. After ESRD onset, there were 142 deaths in the strict blood pressure arm and 182 deaths in the usual blood pressure arm (significant unadjusted hazard ratio for death was 0.72 (95% CI 0.58-0.89)). Overall, there were 212 deaths in the strict blood pressure control arm and 233 deaths in the usual arm (significant unadjusted hazard ratio for death 0.82 (95% CI 0.68-0.98)). Thus, although strict blood pressure control did not delay progression of CKD to ESRD, this strategy was associated with a lower risk of death after ESRD. Hence, long-term post-ESRD outcomes should be considered when formulating blood pressure targets for CKD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25493952      PMCID: PMC4425599          DOI: 10.1038/ki.2014.376

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  25 in total

1.  Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD.

Authors:  J Craig Longenecker; Josef Coresh; Michael J Klag; Andrew S Levey; Alice A Martin; Nancy E Fink; Neil R Powe
Journal:  J Am Soc Nephrol       Date:  2000-03       Impact factor: 10.121

2.  Frailty, dialysis initiation, and mortality in end-stage renal disease.

Authors:  Yeran Bao; Lorien Dalrymple; Glenn M Chertow; George A Kaysen; Kirsten L Johansen
Journal:  Arch Intern Med       Date:  2012-07-23

3.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

4.  The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study.

Authors:  Mark J Sarnak; Tom Greene; Xuelei Wang; Gerald Beck; John W Kusek; Allan J Collins; Andrew S Levey
Journal:  Ann Intern Med       Date:  2005-03-01       Impact factor: 25.391

5.  Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypotheses of the trial. The Multiple Risk Factor Intervention Trial Research Group.

Authors: 
Journal:  JAMA       Date:  1990-04-04       Impact factor: 56.272

Review 6.  The burden of kidney disease: improving global outcomes.

Authors:  Garabed Eknoyan; Norbert Lameire; Rashad Barsoum; Kai-Uwe Eckardt; Adeera Levin; Nathan Levin; Francesco Locatelli; Alison MacLeod; Raymond Vanholder; Rowan Walker; Haiyan Wang
Journal:  Kidney Int       Date:  2004-10       Impact factor: 10.612

7.  Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study.

Authors: 
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

8.  Effect of dialysis dose and membrane flux in maintenance hemodialysis.

Authors:  Garabed Eknoyan; Gerald J Beck; Alfred K Cheung; John T Daugirdas; Tom Greene; John W Kusek; Michael Allon; James Bailey; James A Delmez; Thomas A Depner; Johanna T Dwyer; Andrew S Levey; Nathan W Levin; Edgar Milford; Daniel B Ornt; Michael V Rocco; Gerald Schulman; Steve J Schwab; Brendan P Teehan; Robert Toto
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

9.  Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II Study.

Authors:  Kevin C Abbott; Christopher W Glanton; Fernando C Trespalacios; David K Oliver; Maria I Ortiz; Lawrence Y Agodoa; David F Cruess; Paul L Kimmel
Journal:  Kidney Int       Date:  2004-02       Impact factor: 10.612

10.  How good are the data? USRDS data validation special study.

Authors: 
Journal:  Am J Kidney Dis       Date:  1992-11       Impact factor: 8.860

View more
  32 in total

Review 1.  Clinical significance of 'cardiometabolic memory': a systematic review of randomized controlled trials.

Authors:  Hiroshi Itoh; Isao Kurihara; Kazutoshi Miyashita; Masami Tanaka
Journal:  Hypertens Res       Date:  2017-01-19       Impact factor: 3.872

2.  Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.

Authors:  Elaine Ku; Michael S Lipkowitz; Lawrence J Appel; Afshin Parsa; Jennifer Gassman; David V Glidden; Miroslaw Smogorzewski; Chi-Yuan Hsu
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

3.  The Transition From the Pre-ESRD to ESRD Phase of CKD: Much Remains to Be Learned.

Authors:  Shimi Sharief; Chi-Yuan Hsu
Journal:  Am J Kidney Dis       Date:  2017-01       Impact factor: 8.860

4.  Albuminuria Testing by Race and Ethnicity among Patients with Hypertension with and without Diabetes.

Authors:  Joi Lee; Chi Chu; David Guzman; Valy Fontil; Alexandra Velasquez; Neil R Powe; Delphine S Tuot
Journal:  Am J Nephrol       Date:  2019-06-05       Impact factor: 3.754

5.  Blood Pressure Before Initiation of Maintenance Dialysis and Subsequent Mortality.

Authors:  Keiichi Sumida; Miklos Z Molnar; Praveen K Potukuchi; Fridtjof Thomas; Jun Ling Lu; Vanessa A Ravel; Melissa Soohoo; Connie M Rhee; Elani Streja; John J Sim; Kunihiro Yamagata; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Am J Kidney Dis       Date:  2017-03-11       Impact factor: 8.860

Review 6.  Blood Pressure Parameters and their Associations with Death in Patients with Chronic Kidney Disease.

Authors:  Samaya Qureshi; Robert Lorch; Sankar D Navaneethan
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

7.  Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study.

Authors:  William R Zhang; Timothy E Craven; Rakesh Malhotra; Alfred K Cheung; Michel Chonchol; Paul Drawz; Mark J Sarnak; Chirag R Parikh; Michael G Shlipak; Joachim H Ix
Journal:  Ann Intern Med       Date:  2018-10-23       Impact factor: 25.391

Review 8.  Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.

Authors:  Wan-Chuan Tsai; Hon-Yen Wu; Yu-Sen Peng; Ju-Yeh Yang; Hung-Yuan Chen; Yen-Ling Chiu; Shih-Ping Hsu; Mei-Ju Ko; Mei-Fen Pai; Yu-Kang Tu; Kuan-Yu Hung; Kuo-Liong Chien
Journal:  JAMA Intern Med       Date:  2017-06-01       Impact factor: 21.873

9.  Acute Declines in Renal Function during Intensive BP Lowering and Long-Term Risk of Death.

Authors:  Elaine Ku; Joachim H Ix; Kenneth Jamerson; Navdeep Tangri; Feng Lin; Jennifer Gassman; Miroslaw Smogorzewski; Mark J Sarnak
Journal:  J Am Soc Nephrol       Date:  2018-07-13       Impact factor: 10.121

Review 10.  New treatment paradigms for ADPKD: moving towards precision medicine.

Authors:  Matthew B Lanktree; Arlene B Chapman
Journal:  Nat Rev Nephrol       Date:  2017-10-09       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.